Transdiagnostic Cognitive Remediation Therapy for Patients with Eating Disorders: A Randomized Controlled Trial
Abstract
Background/Objectives: Eating disorders (EDs) are associated with cognitive inefficiencies related to cognitive flexibility, central coherence, and inhibition. Transdiagnostic cognitive remediation therapy (TCRT) is a new adaption of cognitive remediation therapy aimed at addressing these difficulties across ED diagnoses. This study investigates the effects of TCRT as an adjunctive treatment for patients with EDs on cognitive and clinical outcomes. Methods: A randomized controlled trial compared the effect of 9 individual sessions of TCRT in conjunction with treatment as usual (TAU) compared to TAU only for patients with EDs and concurrent cognitive difficulties. Participants were assessed at baseline, post-treatment (12 weeks after baseline), and follow-up (6 months after post-treatment assessment). The outcome measures included neuropsychological tests and self-report questionnaires measuring cognitive difficulties and ED psychopathology. The analysis was in accordance with intention to treat principles. Results: Sixty patients with various ED diagnosis and concurrent cognitive difficulties were recruited. The TCRT group (n = 30) displayed significantly greater improvement in self-reported executive functioning, measured by the Behavior Rating Inventory of Executive Function-Adult version compared to the control group (n = 30). However, no superiority of TCRT was observed on performance-based measures of set shifting, central coherence, or inhibition. Moreover, there was…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 30 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.